Kisspeptin raises testosterone in men. That much has been measured directly, in small studies of healthy volunteers, since 2011. What a study published on August 3, 2026 adds is the harder half of the answer: kisspeptin and testosterone stay linked only while the signal keeps arriving in bursts. Fifteen healthy men were given kisspeptin-10 three different ways. A steady round-the-clock drip for five days, and the pituitary stopped answering. Eight hours on and sixteen hours off, twelve days running, and it kept answering. Timing, not just amount, decided whether anything happened at all.
What the August 2026 study actually did
As of September 6, 2026, the day this article was written, the newest human data on this question comes from a randomized, single-blind, placebo-controlled study run at Imperial College London and published in the European Journal of Endocrinology (Yeung et al., 2026). Fifteen healthy men took part across three linked experiments, and twelve men served as controls.
Everything was given by infusion — a pump, in a research unit, under monitoring. None of it was an injection anyone gave themselves at home, and none of it was testing a treatment. The question was narrower: how would you have to deliver kisspeptin for it to keep working at all?
The three experiments ran like this.
One day. Rising infusion rates over eight hours lifted LH and FSH — the two pituitary hormones that tell the testes to make testosterone — along with testosterone itself. More signal produced more response.
Five days without a break. Testosterone stayed elevated. LH and FSH did not: by the end of the five days they were no different from the placebo arm. The pituitary had quietly stopped answering a signal that never varied.
Twelve days, eight hours on and sixteen hours off. The response held. Mean LH ran about 1.7 points above baseline on day one and was still about 1.1 points above it on day twelve, while the placebo group drifted slightly down (P = 0.003). Then, at the end of the twelve days, the researchers gave a single test dose — and the hormones still moved. The receptor was still listening, not worn out — which is what makes the rest of it interesting.
The authors' own conclusion is careful and worth repeating in their terms: chronic kisspeptin can sustain gonadotropin and testosterone secretion in healthy men for twelve days, and that can inform the development of protocols for treating reproductive disorders. A research plan, in other words. Not a product.
Why a constant drip stops working
Your own kisspeptin does not arrive as a steady stream. It comes in pulses, and everything downstream of it is built to read pulses. Hold the signal flat and the system turns the volume down — the same pharmacology that makes a continuous GnRH drug suppress the reproductive axis instead of driving it harder. What kisspeptin does walks the whole chain if you want the full picture.
The molecule helps enforce the pattern by vanishing quickly. Kisspeptin-10 clears from human blood with a half-life — the time it takes the body to clear half of a dose — of 3.8 minutes in men and 4.1 minutes in women (Jayasena et al., Journal of Clinical Endocrinology & Metabolism 2011). Four minutes is a blink. Kisspeptin-10 covers what a life that short does to everything else about the compound.
A second 2026 paper points the same direction from a different angle. At Massachusetts General Hospital, three healthy men were given kisspeptin-10 continuously for 24 hours. LH climbed five- to eightfold within 12 to 20 hours, then slid back by 13% to 47% from its own peak before the infusion had even finished, with FSH and testosterone rising more modestly alongside (Naveed et al., Hormones 2026). The fade starts inside a day. It is partial rather than a shutdown — LH was still well above where it began — but it is real, and it has now turned up in two independent labs.
What this does and doesn't say about kisspeptin and testosterone
What it says is genuinely new. In men with a working hormone axis, kisspeptin can push the chain — hypothalamus, then pituitary, then testes — hard enough to move testosterone, and a broken-up delivery pattern can keep that going for at least twelve days without exhausting the receptor. The older direct measurement still stands underneath it: a 22.5-hour infusion in healthy men raised testosterone from 16.6 to 24.0 nmol/L (George et al., Journal of Clinical Endocrinology & Metabolism 2011).
What it does not say takes longer.
Fifteen men is fifteen men. All of them healthy, all with a normally functioning axis to begin with. Nobody in these studies had low testosterone, which is the group most people are picturing when they ask the question.
Nothing a person would actually notice was measured. Not energy, not mood, not libido, not muscle, not fertility. The endpoint was a number in a blood tube, tracked over days.
And it was a pump in a hospital, for twelve days. Twelve days is not a year, and an infusion is not a syringe.
Kisspeptin is not testosterone replacement, and it is not PT-141
Two mix-ups are worth clearing up.
The first is testosterone itself. Replacement supplies the hormone from outside, and the body's own production usually dials down in response. Kisspeptin works at the opposite end of the same system: it prods the machinery that makes testosterone, which can only matter if that machinery is capable of answering. Whether yours is happens to be exactly the sort of thing a provider checks with bloodwork before deciding anything. Kisspeptin for men goes into how that plays out in practice.
The second is PT-141. The two sit on the same shelf, and the desire-and-arousal trials people quote for kisspeptin actually used the full-length 54-amino-acid version, infused in a research unit — not the ten-amino-acid fragment, and not at home. PT-141 is a different molecule taking a different route: it acts at melanocortin receptors in the brain, nowhere near the reproductive hormone chain. Same category, different mechanism, different conversation with a prescriber.
What it means if a provider prescribes kisspeptin
The practical lesson from August is unglamorous. How a compound like this is given is a clinical judgment with real physiology behind it, and the instinct most people bring to a vial — more of it, steadier, for longer — is the direction that makes it do less rather than more.
That is the argument for having a clinician in the middle instead of a forum thread. A licensed provider reviews every request against your history, prescribes only if kisspeptin is appropriate for you, and not everyone qualifies. The same person can change course later based on what your labs actually do.
Kisspeptin has never had an FDA-approved product in the United States, and the formulation offered here is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. A licensed provider may still prescribe a compounded formulation when they judge it appropriate — that decision sits between you and your doctor.
What to watch next
Three things, and none of them changes anything this week.
Longer-acting versions. Four minutes is the problem the field keeps trying to engineer around. The Imperial group framed its twelve-day result as groundwork for chronic-administration protocols, not as a finished therapy.
Men who actually have low testosterone. Every human study so far has run in healthy volunteers. An axis that already signals normally is the easiest possible test of a signal.
Numbers. The two newest studies enrolled fifteen men and three men. Work at that scale is genuinely informative about mechanism and tells you almost nothing about who benefits, or by how much.